Latest Anas Younes Stories

Phase I trial establishes dose, catalogues side effects, hints at targeted drug's potentialAn antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine."That level of objective responses to a drug is impressive for a Phase I trial," said study lead author Anas...